Titan Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, TTNP, Titan Pharmaceuticals Inc, priceseries

Titan Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.88
Close
0.89
High
0.93
Low
0.87
Previous Close
0.94
Daily Price Gain
-0.05
YTD High
1.29
YTD High Date
Feb 8, 2022
YTD Low
0.85
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.23
YTD Gain
-20.45%
52 Week High
3.58
52 Week High Date
Mar 11, 2021
52 Week Low
0.85
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.95
52 Week Gain
-68.63%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 26. 2017
297.00
Oct 10. 2017
351.19
10 Trading Days
18.24%
Link
LONG
Jun 6. 2018
164.68
Jun 18. 2018
183.01
8 Trading Days
11.13%
Link
LONG
Oct 15. 2018
40.50
Oct 16. 2018
42.57
1 Trading Days
5.11%
Link
LONG
Oct 17. 2018
42.75
Oct 26. 2018
66.97
7 Trading Days
56.67%
Link
LONG
Sep 3. 2019
14.63
Sep 4. 2019
15.41
1 Trading Days
5.37%
Link
LONG
Dec 27. 2019
5.26
Jan 8. 2020
6.18
7 Trading Days
17.61%
Link
LONG
Mar 2. 2020
12.30
Mar 3. 2020
14.33
1 Trading Days
16.46%
Link
LONG
May 4. 2020
7.62
May 15. 2020
8.57
9 Trading Days
12.41%
Link
LONG
Jun 4. 2020
10.80
Jun 5. 2020
11.99
1 Trading Days
11.00%
Link
LONG
Nov 17. 2020
3.67
Nov 30. 2020
4.52
8 Trading Days
22.90%
Link
LONG
Feb 3. 2021
3.40
Feb 17. 2021
3.63
9 Trading Days
6.71%
Link
Company Information
Stock Symbol
TTNP
Exchange
NasdaqCM
Company URL
http://www.titanpharm.com
Company Phone
6502444990
CEO
Sunil Bhonsle
Headquarters
California
Business Address
400 OYSTER POINT BLVD, SUITE 505, SAN FRANCISCO, CA 94080
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000910267
About

Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It is also developing ProNeura-Ropinirole, an implant to provide long-term delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; ProNeura-Triiodothyronine, an implant to provide long-term delivery of triiodothyronine for the treatment of hypothyroidism; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading